Market Insight Proteins, Antibodies & ADCs

Rewriting The Therapeutic Playbook: Multi-Specifics, Cell Engagers & The Rise Of Next-Gen Modalities

Angus Sinclair

Chief Scientific Officer

LabGenius Therapeutics

Christopher Lloyd

Director

AstraZeneca

Andreas Hollenstein

Senior Principal Scientist, Immunosafety

Roche

Christopher Herring

Vice President of Biology & Safety

T-Therapeutics

Omar Aziz

Scientific Business Director

Charles River Laboratories

27 April, 2026

Watch time: 47 Minutes

Highlights

Takeaways

•Platform vs. product: what will drive success in the multi-specifics & engagers market?

•Emerging modalities meet real-world demand

•Enhancing the activity of T-cell engagers in solid tumours

Moderator:

ANGUS SINCLAIR, Chief Scientific Officer, LabGenius Therapeutics

Panellists:

CHRISTOPHER LLOYD, Director, AstraZeneca

ANDREAS HOLLENSTEIN, Senior Principal Scientist, Immunosafety, Roche

CHRISTOPHER HERRING, Vice President of Biology & Safety, T-Therapeutics

OMAR AZIZ, Scientific Business Director, Charles River Laboratories

PREMIUM CONTENT

Want that extra level of detail?
Subscribe and get access to full length presentations and write-ups giving you the insights to stay ahead of the curve.

Please note once we have received payment it can take 24 hours for your account to be updated to the premium access.

Upgrade

Full Video Transcript